MariMed CEO buys 40,000 company shares
MariMed Inc. President and CEO Jon R. Levine reported an open-market purchase of 40,000 shares of common stock at $0.075 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MariMed Inc. President and CEO Jon R. Levine reported an open-market purchase of 40,000 shares of common stock at $0.075 per share. Following this trade, he owns 21,247,986 shares directly. A separate 6,684,640 shares are held by the Jon Levine Family Trust for his spouse and children, which he disclaims as beneficially owned.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common stock | 40,000 | $0.075 | $3K |
| holding | Common stock | -- | -- | -- |
Footnotes (1)
- F1. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Key Figures
Key Terms
open-market purchase financial
beneficial ownership financial
Section 16 regulatory
trust financial
indirect ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MariMed (MRMD) CEO Jon R. Levine report?
Does Jon R. Levine’s Form 4 include any stock option or derivative transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.